Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $1.0 billion.

  • Madrigal Pharmaceuticals' Liabilities and Shareholders Equity rose 26.95% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 13.37%. This contributed to the annual value of $1.0 billion for FY2024, which is 62.71% up from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.0 billion, which was up 62.71% from $640.5 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $1.0 billion for FY2024, and its period low was $273.3 million during FY2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $640.5 million (2023), whereas its average is $681.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 35.08% in 2020, then spiked by 76.67% in 2023.
  • Madrigal Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $287.0 million in 2020, then fell by 4.76% to $273.3 million in 2021, then spiked by 32.65% to $362.6 million in 2022, then surged by 76.67% to $640.5 million in 2023, then spiked by 62.71% to $1.0 billion in 2024.